SecBot SecBot
S-3 ·Filed Jul 2, 2026

INO

INOVIO PHARMACEUTICALS, INC.
BEARISH
Impact 6/10
Horizonmonths Processed4mo ago SEC0001193125-26-294457
Shelf registration, potential dilution
Actionable Insight ▼ Bearish

Given the company's history of frequent dilutive raises, a sub-$100M market cap, no product revenue, and a binary PDUFA event four months away, traders should expect further stock-price pressure from potential at-the-market or underwritten offerings. Monitor any prospectus supplement for specific offering size and pricing, and watch for risk of full valuation reset if the FDA does not approve INO-3107 under accelerated approval.

DirectionBearish
Confidencehigh
Horizonmonths

Drug in focus

INO drug pipeline →

VOCERYQ

● Neutral Named in this S-3
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
Next catalyst
None dated

What to watchWith the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.22
T+0 close · Jul 2, 2026 · via day close
Latest settled
−4.10%
T+60 · $1.17
Vs SPY
−7.67%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $1.22entry
  2. T+1 · 4mo ago −4.92%α −5.79% · $1.16
  3. T+5 · 4mo ago −2.46%α −3.39% · $1.19
  4. T+20 · 4mo ago −46.23%α −45.81% · $0.6560
  5. T+60 · 7w ago −4.10%α −7.67% · $1.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inovio Pharmaceuticals (INO) filed a universal shelf registration statement on Form S-3 on July 2, 2026, to raise up to $300,000,000 from the sale of common stock, preferred stock, debt securities, and/or warrants over time. This follows a pattern of frequent capital raises (at least four underwritten offerings in the prior 18 months through March 2026 per the 10-Q) and comes as the company awaits an October 30, 2026 PDUFA date for its lead BLA candidate INO-3107. The filing signals ongoing and substantial dilution for existing shareholders, funding development and working capital needs at a sub-$100M market cap.

Key Financial Metrics

Offering Size
$300.0M

Key Facts

  • Shelf registration allows for up to $300,000,000 in aggregate offerings of common stock, preferred stock, debt securities, and warrants.
  • Common stock closed at $1.19/share on July 1, 2026, with a market cap of approximately $98M.
  • The company has a history of dilutive financing: the 10-Q for Q1 2026 discloses at least five capital raises (December 2024, April 2025, July 2025, November 2025, April 2026) in the prior 18 months using common stock and warrants.
  • As of March 31, 2026, the company had $33.9M in cash and equivalents and no product revenue.
  • Lead pipeline candidate INO-3107 has a PDUFA target date of October 30, 2026, but the FDA may determine it is not eligible for accelerated approval, which would require a costly Phase 3 trial.
  • The company is a smaller reporting company with no commercial-stage product and expects no material product revenues until INO-3107 or other candidates are approved.

Financial Impact

Shelf registration of up to $300M represents ~306% of current market cap ($98M). Actual dilution depends on timing and pricing of future takedowns.

dilutionshare countmarket cap

Risk Factors

  • Potential massive dilution: $300M shelf relative to $98M market cap can destroy existing equity value if fully utilized.
  • PDUFA risk for INO-3107 on October 30, 2026; if the FDA denies accelerated approval, a costly Phase 3 trial would be required with no clear path to revenue.
  • No product revenue and a limited cash runway ($33.9M as of Q1 2026) means the company will likely need to tap this shelf repeatedly, compounding dilution.
  • Pattern of serial capital raises (numerous offerings in prior 18 months) suggests a structural need for external financing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-294457
Document: d141328ds3.htm0001193125-26-294457
Document: d141328dex48.htm0001193125-26-294457

Track record

20 reports on INO

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.52% at T+20 after the Jul 13, 2026 report. 8 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
  4. Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
  5. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  6. Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  7. Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  8. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  9. Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  10. Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026